5393-81-7

Usage

Uses

Used in Pharmaceutical Industry:
2-HYDROXYDECANOIC ACID is used as an active pharmaceutical ingredient for its potential therapeutic effects. The hydroxy group at position 2 allows for interactions with specific biological targets, making it a promising candidate for the development of new drugs.
Used in Cosmetics Industry:
2-HYDROXYDECANOIC ACID is used as an ingredient in the cosmetics industry for its moisturizing and emollient properties. The hydroxy group can form hydrogen bonds with water molecules, helping to retain moisture and improve the skin's appearance.
Used in Chemical Synthesis:
2-HYDROXYDECANOIC ACID is used as a building block in the synthesis of various chemical compounds. Its unique structure allows for further functionalization and modification, making it a versatile starting material for the production of specialty chemicals and intermediates.
Used in Energy Storage:
2-HYDROXYDECANOIC ACID can be used in the development of novel energy storage materials, such as lithium-ion batteries. The hydroxy group can potentially be involved in electrochemical reactions, contributing to the overall performance of the energy storage system.
Used in Biodegradable Polymers:
2-HYDROXYDECANOIC ACID can be used as a monomer in the synthesis of biodegradable polymers. The hydroxy group can be used to create ester or ether linkages, resulting in polymers with improved biodegradability and environmental compatibility.
Used in Food Industry:
2-HYDROXYDECANOIC ACID can be used as an additive in the food industry for its emulsifying and stabilizing properties. The hydroxy group can interact with both polar and non-polar molecules, helping to improve the texture and shelf life of various food products.

InChI:InChI=1/C10H20O3/c1-2-3-4-5-6-7-8-9(11)10(12)13/h9,11H,2-8H2,1H3,(H,12,13)

Upstream product

• 247180-28-5 2,4-dioxo-decanoic acid 
• 42512-96-9 ethyl 2-acetoxydecanoate 
• 17702-88-4 rac-2-aminodecanoic acid 
• 97-93-8 triethylaluminum 
• 95979-06-9 (2SR,3SR)-3-heptyl-oxirane-2-carboxylic acid 
• 104228-20-8 2-Propionyloxy-decanoic acid methyl ester 
• 104228-13-9 2-Propionyloxy-decanoic acid ethyl ester 
• 104228-14-0 2-Butyryloxy-decanoic acid ethyl ester 
• 110-38-3 decanoic acid ethyl ester 
• 334-48-5 1-decanoic acid 
• 2623-95-2 2-bromodecanoic acid 
• 124-19-6 nonan-1-al 
• 75234-11-6 (±)-2-hydroxydecanenitrile 
• 5440-55-1 acetylamino-octyl-malonic acid diethyl ester 

Downstream Products

• 71271-24-4 2-Hydroxycaprinsaeure-methylester 
• 112-05-0 nonanoic acid 
• 141329-99-9 N-phenyl-2-hydroxy-decanamide 
• 124-19-6 nonan-1-al 
• 1119-86-4 1,2-decanediol 
• 70267-24-2 (R)-2-hydroxydecanoic acid 
• 333-60-8 2-oxodecanoic acid 
• 124-38-9 carbon dioxide 
• 7732-18-5 water 
• 260055-48-9 2-hydroxy-decanoic acid benzyl ester 
• 260055-47-8 2-trifluoromethanesulfonyloxy-decanoic acid benzyl ester 
• 2404-44-6 1,2-Epoxydecane 
• 17702-88-4 rac-2-aminodecanoic acid 
• 16725-36-3 methyl 2-methoxyhexadecanoate 

Relevant academic research and scientific papers

Novel insights into oxidation of fatty acids and fatty alcohols by cytochrome P450 monooxygenase CYP4B1

CYP4B1 is an enigmatic mammalian cytochrome P450 monooxygenase acting at the interface between xenobiotic and endobiotic metabolism. A prominent CYP4B1 substrate is the furan pro-toxin 4-ipomeanol (IPO). Our recent investigation on metabolism of IPO related compounds that maintain the furan functionality of IPO while replacing its alcohol group with alkyl chains of varying structure and length revealed that, in addition to cytotoxic reactive metabolite formation (resulting from furan activation) non-cytotoxic ω-hydroxylation at the alkyl chain can also occur. We hypothesized that substrate reorientations may happen in the active site of CYP4B1. These findings prompted us to re-investigate oxidation of unsaturated fatty acids and fatty alcohols with C9–C16 carbon chain length by CYP4B1. Strikingly, we found that besides the previously reported ω- and ω-1-hydroxylations, CYP4B1 is also capable of α-, β-, γ-, and δ-fatty acid hydroxylation. In contrast, fatty alcohols of the same chain length are exclusively hydroxylated at ω, ω-1, and ω-2 positions. Docking results for the corresponding CYP4B1-substrate complexes revealed that fatty acids can adopt U-shaped bonding conformations, such that carbon atoms in both arms may approach the heme-iron. Quantum chemical estimates of activation energies of the hydrogen radical abstraction by the reactive compound 1 as well as electron densities of the substrate orbitals led to the conclusion that fatty acid and fatty alcohol oxidations by CYP4B1 are kinetically controlled reactions.

Controlling the Regioselectivity of Fatty Acid Hydroxylation (C10) at α- and β-Position by CYP152A1 (P450Bsβ) Variants

Regioselective hydroxylation on inactivated C?H bonds is among the dream reactions of organic chemists. Cytochrome P450 enzymes (CYPs) perform this reaction in general with high regio- and stereoselectivity (e. g. for steroids as substrates). Furthermore, enzyme engineering may allow to tune the properties of the enzyme. Regioselective hydroxylation of shorter or linear molecules (fatty acids), however, remains challenging even with this enzyme class, due to the high similarity of the substrate's backbone carbons and their conformational flexibility. CYPs hydroxylating fatty acids selectively in the chemically more distinct α- or ω- position are well described. In contrast, selective in-chain hydroxylation of fatty acids lacks precedence. The peroxygenase CYP152A1 (P450Bsβ) is a family member that displays fatty acid hydroxylation at both, the α- and β-position, with preference for the α-position. Herein we report the influence of hydrophobic active site residues on the hydroxylation pattern of this enzyme. By site directed mutagenesis and combination of the libraries, double and triple mutation variants were identified, which hydroxylated decanoic acid (C10) with improved regio-selectivity in the β-position. Variants were identified with a 10-fold increase of the β-regioselectivity (expressed as α/β-ratio) compared to the wild type. In total 103 variants of CYP152A1 (P450Bsβ) were investigated.

Preparative Asymmetric Synthesis of Canonical and Non-canonical α-amino Acids Through Formal Enantioselective Biocatalytic Amination of Carboxylic Acids

Chemical and biocatalytic synthesis of non-canonical α-amino acids (ncAAs) from renewable feedstocks and using mild reaction conditions has not efficiently been solved. Here, we show the development of a three-step, scalable and modular one-pot biocascade for linear conversion of renewable fatty acids (FAs) into enantiopure l-α-amino acids. In module 1, selective α-hydroxylation of FAs is catalyzed by the P450 peroxygenase P450CLA. By using an automated H2O2 supplementation system, efficient conversion (46 to >99%; TTN>3300) of a broad range of FAs (C6:0 to C16:0) into valuable α-hydroxy acids (α-HAs; >90% α-selective) is shown on preparative scale (up to 2.3 g L?1 isolated product). In module 2, a redox-neutral hydrogen borrowing cascade (alcohol dehydrogenase/amino acid dehydrogenase) allowed further conversion of α-HAs into l-α-AAs (20 to 99%). Enantiopure l-α-AAs (e.e. >99%) including the pharma synthon l-homo-phenylalanine can be obtained at product titers of up to 2.5 g L?1. Based on renewables and excellent atom economy, this biocascade is among the shortest and greenest synthetic routes to structurally diverse and industrially relevant ncAAs. (Figure presented.).

Preparative Asymmetric Synthesis of Canonical and Non-canonical a-amino Acids through Formal Enantioselective Biocatalytic Amination of Carboxylic Acids

Chemical and biocatalytic synthesis of non-canonical a-amino acids (ncAAs) from renewable feedstocks and using mild reaction conditions has not efficiently been solved. Here, we show the development of a three-step, scalable and modular one-pot biocascade for linear conversion of renewable fatty acids (FAs) into enantiopure l-a-amino acids. In module 1, selective a-hydroxylation of FAs is catalyzed by the P450 peroxygenase P450CLA. By using an automated H2O2 supplementation system, efficient conversion (46 to >99%; TTN>3300) of a broad range of FAs (C6:0 to C16:0) into valuable a-hydroxy acids (a-HAs; >90% a-selective) is shown on preparative scale (up to 2.3 gL1 isolated product). In module 2, a redox-neutral hydrogen borrowing cascade (alcohol dehydrogenase/amino acid dehydrogenase) allowed further conversion of a-HAs into l-a-AAs (20 to 99%). Enantiopure l-a-AAs (e.e. >99%) including the pharma synthon l-homo-phenylalanine can be obtained at product titers of up to 2.5 gL1. Based on renewables and excellent atom economy, this biocascade is among the shortest and greenest synthetic routes to structurally diverse and industrially relevant ncAAs.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Personal care compositions comprising solid particles enterapped in a gel network

The present invention relates to a personal care composition comprising a three dimensional gel polymeric network comprising: a. a polymer; b. one or more solid particles that are entrapped within said polymer during polymerization of said polymer; and c. a solvent in which said polymer is dispersed. Another embodiment further includes at least one second colorant that is substantially similar to an at least one first colorant which is a solid particle and wherein said second colorant is dispersed within said composition but is not entrapped in said polymer and is separate and distinct from said network. In contrast, a third embodiment allows for the at least one second colorant to be substantially different from the at least one first colorant.

Method and product for skin lightening

A method and cosmetic product for lightening skin is provided, the method including wiping the skin with a cosmetic towelette. Impregnated on the towelette is an alpha-hydroxy carboxylic acid or salt thereof and a sunscreen agent.

COSMETIC COMPOSITIONS CONTAINING A SILOXANE ELASTOMER

A skin treatment composition is provided which includes a crosslinked non-emulsifying siloxane elastomer, a volatile siloxane and at least 50% by weight of water. Inclusion of the elastomer provides a unique liquid/powdery feel when rubbed into the skin.

Cosmetic compositions

The present invention relates to pigmented emulsion cosmetic compositions containing emulsifying silicone elastomers that provide a natural appearance to the skin upon application. In particular, these cosmetic compositions are formulated such that agglomeration of the pigment upon application to the skin is minimized.